

# The Role of Curcumin on Rhinovirus (HRV14) Protein Inhibition by Targeting Host and Viral Proteins

Deeptimayi Dash <sup>1,\*</sup> , Rojalin Pattanayak <sup>1</sup> , Laxminandan Satpathy <sup>2</sup> , Siba Prasad Parida <sup>3,\*</sup> 

<sup>1</sup> Department of Zoology, College of Basic Science and Humanities, Odisha University of Agriculture and Technology, Bhubaneswar, Odisha, 751 003 India; dashdeeptimayi98@gmail.com (D.D.); Pattanayak.rojalin@gmail.com (R.P.);

<sup>2</sup> Department of Zoology, Synergy Institute of Science and Management, Dhenkanal, Odisha, 759 001 India; laxminandansatpathy@gmail.com (L.S.);

<sup>3</sup> Department of Zoology, School of Applied Sciences, Centurion University of Technology and Management, Bhubaneswar, Odisha, 752 050 India; paridasp@gmail.com (S.P.P.);

\* Correspondence: dashdeeptimayi98@gmail.com (D.D.); paridasp@gmail.com (S.P.P.);

Scopus Author ID 58174029000

Received: 27.06.2023; Accepted: 7.07.2024; Published: 28.08.2024

**Abstract:** This *in-silico* analysis aims to explain curcumin's effects and how (HRV14) protein may cure the common cold fever. Human rhinoviruses predominantly cause the common cold and are responsible for the manifestation of maximum upper respiratory tract viral infections. Human rhinovirus belongs to the Picornaviridae family and is part of the genus *Enterovirus*. More than 150 HRV variants are categorized as species A, B, and C. Exacerbations of chronic obstructive pulmonary disease, asthma, and cystic fibrosis have also been linked to rhinoviruses. In this research work, turmeric is selected as the plant source, and curcumin is a phytochemical constituent selected for the *in-silico* analysis against the common cold. Humans have relied on plants for medicinal purposes since the dawn of time. *Curcuma longa* L. is the scientific name for turmeric, which belongs to the family Zingiberaceae of plants. It is grown in almost every country on this planet, with the majority of production taking place in Asia, Europe, North America, and the United States. It is a common spice and aromatic crop, and dried seeds are used in various foods, medicines, and beverage formulations. It has many therapeutic properties, such as anti-carcinogenic, anti-diabetic, hypocholesterolemic, anti-microbial, and antioxidant activities. In this research, an *in silico* analysis of curcumin against rhinovirus capsid protein HRV14 was performed using Auto Dock Vina software. The ligands were successfully bound to the active site of the rhinovirus capsid protein HRV14 and showed no toxicity and good drug scores. So, the study signifies that this ligand may be tried clinically and may act as a potential drug applicant against the common cold.


**Keywords:** rhinovirus; common cold; phytochemicals; turmeric (*Curcuma longa* L.); *in-silico* analysis.

© 2024 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).


## 1. Introduction

The common cold is a self-limiting, acute viral illness that affects the upper respiratory tract, including the nose, sinuses, pharynx, and larynx. The virus is transmitted by direct or indirect hand contact with an infected person's secretions or by inhaling the secretions and virus as an aerosol [1]. Rhinovirus infection mainly targets bronchial epithelial cells. More than half of all upper respiratory system infections are caused by HRVs. The illness is known as a common cold, and it normally lasts 5–7 days. Nasal congestion, sneezing, coughing, and a sore

throat are some of the symptoms. However, 12-32 percent of HRV infections in children under the age of four are asymptomatic [2]. According to information from the Centers for Disease Control and Prevention (CDC), the common cold can be caused by various respiratory viruses [3,4]. Human rhinovirus, human parainfluenza viruses, common human coronaviruses, respiratory syncytial virus, human metapneumovirus, and adenovirus are among the viruses that can cause colds. Sinus, ear infections, and asthma have also been linked to rhinoviruses [5]. It is the general cause of the common cold and the worsening of asthma and COPD [6]. HRVs have a single-stranded positive-sense RNA genome and are non-enveloped (Figure 1, Figure 2 (A), Figure 2 (B)). An icosahedral protein capsid made up of 60 copies of each of the four viral proteins VP1-VP4 protects the genome [2,7]. More than 150 HRV variants are categorized as species A, B, and C based on phylogeny [8]. Such flu symptoms appear similar to even a cold, but they are usually more severe and less likely to have a sinus infection. Some evidence supports the use of surgical masks [9-13]. There seems to be no cure, but the symptoms can be managed. When taken soon after the onset of side effects, zinc can help to shorten the duration and severity of symptoms [14-18].



**Figure 1.** Icosahedral HRV14 rhinovirus protein capsid.



**(a)**



**(b)**


**Figure 2.** 3D structures of HRV14 rhinovirus capsid protein using (a) PubChem; (b) BIOVIA Discovery Studio.

Plants have the inborn quality to treat diseases and integrate numerous non-enzymatic rust inhibitors or antioxidants competent in devaluating ROS-induced oxidative damage. WHO approximates that 80% of people still believe in herbal medication for their requirements primarily because they have fewer negative effects and work better with the body and endure them. Medicinal plants include all those plants used as herbs and contain substances used for therapeutic purposes. These plants might eventually result in the creation of new drugs for the presence of some compounds that serve as pharmacological precursors. These plants include *Aloe vera*, *Camellia sinensis*, *Curcuma longa*, *Mentha pulegium*, *Nigella sativa*, *Allium sativum*, *Zingiber officinale*, *Artemisia absinthiu*, and many other plants. So, those plants with medicinal properties that qualify as therapeutic agents or drugs are considered medicinal plants

[19,20]. We favor plants because there are so many of them that make it simple to treat illness without any adverse effects. Higher plants' antioxidant defense system comprises enzymes and low-molecular-weight substances (alkaloids, flavonoids, vitamins, and other phytochemicals) [21-24]. As a component of their enzymatic defense system, plants neutralize, eliminate, or scavenge oxy-intermediates [25-27]. Turmeric (*Curcuma longa* L.), a popular South Asian spice, is a member of the ginger family Zingiberaceae having three main curcuminoids, namely curcumin, bis-desmethoxycurcumin, and desmethoxycurcumin (Figure 3 and Figure 4) [28, 29].



**Figure 3.** *Curcuma longa* L. (turmeric).



**Figure 4.** Chemical structure of curcumin using GaussView 4.1.

## 2. Materials and Methods

### 2.1. Ligand selection and filtration.

Curcumin from *Curcuma longa* L. was taken as a ligand for docking analysis. The three-dimensional coordinates for ligands were obtained from the PubChem database (<https://pubchem.ncbi.nlm.nih.gov>).

### 2.2. Drug likeness and toxicity prediction of the ligands.

The pharmacologically active substituents are characterized by calculating steric, hydrophobic, electronic, and hydrogen bonding properties as well as by the drug-likeness score. The drug-likeness score theory helps optimize pharmaceutical and pharmacokinetic properties, such as chemical stability, solubility, distribution profile, and bioavailability. These parameters are responsible for about 60 percent of failures of all drugs in the clinical phases. So the prediction of OSIRIS property explorer (<https://www.organic-chemistry.org>) explores the drug-likeness of the select ligands (Table 1). The molecular descriptors have developed as rationally predictive and informative, for example, Lipinski's Rule-of-Five. Lipinski's rule of five describes the important molecular properties required for the drug's pharmacokinetics. Lipinski's rule states that the drug to have a good pharmacokinetic profile should not have more than one violation of the following criteria: (i) not more than 5 hydrogen-bond donors,

(ii) not more than 10 hydrogen-bond acceptors, (iii) molecular weight should be less than 500 daltons (Da), and (iv) the partition coefficient (log P) not greater than 5 [30-34] (Table 2).

**Table 1.** Toxicity analysis of the screened ligands generated by Osiris property explorer.

Ligand Number	Ligand CID	Mutagenic	Tumorigenic	Irritant	Reproductive
1	969516	No	No	No	No

**No:** These ligands possess no high-risk or medium-risk fragments.

**Mutagenic:** Whether the ligand has any fragment that can cause mutation.

**Tumorigenic:** Whether the ligand has any fragment that can cause tumors.

**Irritant:** Whether the ligand has any fragment that can cause irritation.

**Reproductive effect:** Whether the ligand has any fragment that can cause any reproductive effect.

**Table 2.** Lipinski's rule requires important molecular properties for the drug's pharmacokinetics.

Compound name	H-bond donor count	H-bond acceptor count	Partition coefficient (XLogP)	No. of rotational bonds	Molecular Weight (G/mol)	Lipinski's rules
Curcumin	<5	<10	<5	2	<500	Pass

### 2.3. Protein preparation.

The three-dimensional crystallographic structures of rhinovirus (common cold) were retrieved from the RCSB PDB database (<https://www.rcsb.org>) and were used for further processing. In protein structure modification initially requires various tasks such as insertion of atoms missing in incomplete residues, deletion of alternate conformations, missing loop region modeling, protonation of titrable residues, prediction of pKa (a measure of negative logarithm of the dissociation constant of an acid), providing standardized atom names and removal of water molecules or heteroatoms and addition of hydrogen atoms. The preparation of proteins was performed with the aid of CHARMM force fields [35-38].

### 2.4. Protein-ligand docking.

Discovery Studio 2.0 (Accelrys, USA) (<http://www.3dsbiovia.com>) was employed for the *in silico* and post-docking visualization. The molecular docking study was completed by a Discovery Studio LibDock program that revealed the bioactive binding sites of receptors. In LibDock, two protein site features, polar and apolar, are available and are called hotspots. Further, curcumin interacted with the polar and apolar sites of receptors. Additionally, to identify specific interacting residues of the receptor with a bound ligand, a 2D diagram of the docking study was carried out.

### 2.5. Visualisation

The protein target was validated with AutoDockVina (<http://autodock.scripps.edu/resources/adt>), an open-source software designed by Dr. Oleg Trott. This docking process was based on root mean square deviation (RMSD) value determination. The RMSD value less than 2Å was used for considering the best docking position between INCQ and ligands, and the schematic diagrams of protein-ligand interactions were prepared using BIOVIA Discovery Studio.


### 3. Results

The data gathered from the respondents were examined with the targets and objectives of the study in view, and the aftereffects of the evaluation and investigation in accordance with the study's objectives are exhibited under the accompanying headings.

#### 3.1. *In silico* analysis of curcumin against common cold 'HRV14' protein.

Fifteen flavonoids were evaluated for their pharmacokinetic profile based on Orisis property explorer and Lipinski's rule of five using MedChem Designer software. Out of those 15, Ligand CID No. 969516, i.e., curcumin, is selected for further studies as it passes both tests. Curcumin binds with the target site (HRV14).

The present study subjected curcumin to molecular docking at the active site of rhinovirus (HRV14) protein structures. The docking results showed that curcumin interacted with HRV14 with a good docking score of 93.14 Kcal/mol (Table 3). The curcumin compound's methoxyphenyl group is involved in forming hydrogen bonds with the Ser175, Tyr197, Ser126, Val188, and Pro189 amino acids of the HRV14 enzyme. In molecular docking analysis, different types of bond interactions, such as hydrogen bond interaction, hydrophobic bond interaction, Van der Waals interaction, and  $\pi$ - $\pi$  bond interaction, were also examined with their amino acids' residues (Figure 5). We found that Met221, Val191, Ser126, Pro174, Ala150, Val176, and Phe186 were involved in binding with the active site pocket of HRV14. Our results were similar to previous molecular docking studies [39].



**Figure 5.** 3D and 2D poses shows binding interactions of curcumin with the HRV14 enzyme (common cold).

**Table 3.** Molecular docking of curcumin with HRV14 enzyme (common cold).

Structure	Docking score (Kcal/mol)	Hydrogen bond		Hydrophobic interactions amino acid
		Amino acid	Bond length (Å)	
Curcumin	93.18	O14-Tyr197	2.70246	Met221, Val191, Ser126, Pro174, Ala150, Val176, Phe186
		C13-Pro189	3.23032	
		C14-Val188	3.65591	
		O34-Ser175	3.77072	

#### 3.2. Hydrogen bonding interactions.

Curcumin inhibits the viral protease by forming multiple essential hydrogen bonds with its amino acid constituents. O14-Tyr197: With a length of 2.70246 Å, this bond demonstrates a robust interaction that maintains curcumin binding to the protease active site. C13-Pro189: This

contact helps ensure that curcumin is positioned correctly within the protease, with a bond length of 3.23032 Å. C14-Val188: Curcumin is additionally anchored by this bond, which is located at 3.65591 Å, increasing its inhibitory potency. O34-Ser175: A further stabilizing interaction is highlighted by the bond length of 3.77072 Å, assuring strong binding.

### 3.3. Hydrophobic interactions.

Curcumin's binding affinity is also significantly influenced by hydrophobic interactions. Met221, Val191, Ser126, Pro174, Ala150, Val176, and Phe186 are important residues in these interactions. Through these interactions, the curcumin inhibitory effect is enhanced by stabilizing it within the hydrophobic regions of the viral protease. The compound's efficacy and toxicity profile support the ongoing efforts to develop curcumin as a medicinal countermeasure.

## 4. Discussion

This is the first study to compare curcumin's efficacy in treating human rhinovirus. Curcumin, a polyphenolic molecule produced from spice turmeric, has drawn attention for its broad-spectrum antiviral capabilities; this study was the first to assess its efficacy. 93.18 Kcal/mol is the docking score for curcumin, which indicates that it has significant potential in suppressing Human Rhinovirus (HRV14). This score indicates a significant binding affinity, indicating that curcumin inhibits the lifecycle of HRV14 by efficiently interacting with important viral proteins. Due to the widespread nature of rhinovirus infections and their influence on world health, which are the primary causes of colds, the inhibition of Human Rhinovirus (HRV14) by curcumin is especially noteworthy. The process of determining a tiny molecule's preferred orientation when it is coupled to a second molecule's binding site is known as molecular docking. It is one of the methods for creating structure-based drugs that is most commonly employed.

## 5. Conclusions

From the *in-silico* analysis, we concluded that curcumin taken for virtual screening effectively binds with the rhinovirus capsid protein 1NCQ. So, this may be a potential drug candidate against the common cold as it has no toxicity and possesses a good drug score. The bioactive compounds present in curcumin can be traced to its medicinal uses, but more research and analysis are needed. This bioactive compound making is crucial in medicine because it helps reduce reliance on synthetic medicines and several costly therapies for diseases. The issues that have appeared as a result of the analysis and discoveries have, thus far, reopened the way to fresh research. It's dreadful to say that all has been done, that vital data has been acquired and presented, but there is still room to learn about more phytochemicals, evaluate them, and test them on a variety of new emergent maladies around the world to eradicate them. *In vitro*, investigations make it easier to develop pharmaceuticals and learn about the therapeutic benefits of nutri-compounds from plants like curcumin without harming living organisms. As a response, using commercial software and web tools, the *in-silico* approach used in this study aided in the discovery of ligands for the common cold. This technique saves money and time by decreasing the cost and time it takes to design a treatment and assess its likelihood before entering clinical trials.

## Funding

This research received no external funding.

## Acknowledgments

This research has no acknowledgement.

## Conflicts of Interest

The authors declare no conflict of interest.

## References

1. Heikkinen, T.; Järvinen, A. The common cold. *Lancet* **2003**, *361*, 51-59, [https://doi.org/10.1016/S0140-6736\(03\)12162-9](https://doi.org/10.1016/S0140-6736(03)12162-9).
2. Jacobs Samantha, E.; Lamson Daryl, M.; St. George, K.; Walsh Thomas, J. Human Rhinoviruses. *Clin. Microbiol. Rev.* **2013**, *26*, 135-162, <https://doi.org/10.1128/cmr.00077-12>.
3. Centers for Disease, C.; Prevention. CDC yellow book 2020: health information for international travel. Brunette, G.W., Nemhauser, J.B., Eds.; Oxford University Press, **2019**. <https://doi.org/10.1093/med/9780190928933.001.0001>.
4. Archibald, L.K.; Jarvis, W.R. Health Care–Associated Infection Outbreak Investigations by the Centers for Disease Control and Prevention, 1946–2005. *Am. J. Epidemiol.* **2011**, *174*, S47-S64, <https://doi.org/10.1093/aje/kwr310>.
5. Prasad, S.; Lownik, E.; Ricco, J. Viral Infections of the Respiratory Tract. In *Family Medicine: Principles and Practice*, Paulman, P.M., Taylor, R.B., Paulman, A.A., Nasir, L.S., Eds.; Springer International Publishing, Cham, **2017**; 507-517, [https://doi.org/10.1007/978-3-319-04414-9\\_41](https://doi.org/10.1007/978-3-319-04414-9_41).
6. Mirabelli, C.; Scheers, E.; Neyts, J. Novel therapeutic approaches to simultaneously target rhinovirus infection and asthma/COPD pathogenesis. *F1000Research* **2017**, *6*, 1860, <https://doi.org/10.12688/f1000research.11978.1>.
7. Parija, S.C. Picornaviruses. In *Textbook of Microbiology and Immunology*, Parija, S.C., Ed.; Springer Nature Singapore, Singapore, **2023**; 781-795, [https://doi.org/10.1007/978-981-19-3315-8\\_55](https://doi.org/10.1007/978-981-19-3315-8_55).
8. Palmenberg, A.C.; Spiro, D.; Kuzmickas, R.; Wang, S.; Djikeng, A.; Rathe, J.A.; Fraser-Liggett, C.M.; Liggett, S.B. Sequencing and Analyses of All Known Human Rhinovirus Genomes Reveal Structure and Evolution. *Science* **2009**, *324*, 55-59, <https://doi.org/10.1126/science.1165557>.
9. Karimian, H.; Fan, Q.; Li, Q.; Chen, Y.; Shi, J. Spatiotemporal transmission of infectious particles in environment: A case study of Covid-19. *Chemosphere* **2023**, *335*, 139065, <https://doi.org/10.1016/j.chemosphere.2023.139065>.
10. Le Sage, V.; Lowen, A.C.; Lakdawala, S.S. Block the Spread: Barriers to Transmission of Influenza Viruses. *Annu. Rev. Virol.* **2023**, *10*, 347-370, <https://doi.org/10.1146/annurev-virology-111821-115447>.
11. Manesh, A.; Mulyil, D. E.; Singh, B.; Oommen, A. M.; Chowdhury, S. D.; Brett-Major, D. COVID-19. *Manson's Tropical Infectious Diseases*, 24<sup>th</sup> Edition, Farrar, J., Hotez, P. J., Junghanss, T., Kang, G., Lalloo, D., White, N. J., Gracia, P. J., Eds.; Elsevier Health Sciences, United Kingdom, **2023**; 312-325, <https://www.mea.elsevierhealth.com/mansons-tropical-diseases-9780702079597.html>.
12. Singh, K. *Do Face Masks Really Work?: An Introduction to the New World Order*, 1<sup>st</sup> Edition. Notion Press, Chennai, India, **2023**; 3-25.
13. Tang, J.W.; Marr, L.C.; Tellier, R.; Dancer, S.J. Airborne transmission of respiratory viruses including severe acute respiratory syndrome coronavirus 2. *Curr. Opin. Pulm. Med.* **2023**, *29*, 191-196, <https://doi.org/10.1097/MCP.0000000000000947>.
14. El Sabbagh, E.; El-Sayed, M.; Elbaz, T. Vitamins and minerals: A means for surviving the COVID-19 pandemic or just a myth?. *J. Infect. Dev. Ctries.* **2022**, *16*, 782-786, <https://doi.org/10.3855/jidc.14692>.
15. Singh, B.; Eshaghian, E.; Chuang, J.; Covasa, M. Do Diet and Dietary Supplements Mitigate Clinical Outcomes in COVID-19?. *Nutrients* **2022**, *14*, 1909, <https://doi.org/10.3390/nu14091909>.
16. Balasubramanian, A.; Holbrook, J.T.; Canning, B.J.; Que, L.G.; Castro, M.; Make, B.J.; Rogers, L.; Busk, M.F.; Rea, A.; McCook-Veal, A.A.; He, J.; McCormack, M.C.; Wise, R.A. Efficacy and tolerability of zinc

- acetate for treatment of chronic refractory cough: pilot randomised futility trial. *ERJ Open Res.* **2023**, *9*, <https://doi.org/10.1183/23120541.00678-2022>.
17. Lindberg, B.F.; Nelson, I.; Ranstam, J.; Riker, D.K. Early intervention with ColdZyme mouth spray after self-diagnosis of common cold: A randomized, double-blind, placebo-controlled study. *PloS one* **2023**, *18*, e0279204, <https://doi.org/10.1371/journal.pone.0279204>.
  18. Radhakrishnan, A.; Spencer, S.; Yanamala, N.; Malepati, S. Evaluating the Efficacy and Safety of EZC Pak, a 5-Day Combination Echinacea-Zinc-Vitamin C Dose Pack with or without Vitamin D, in the Management of Outpatient Upper Respiratory Infections. *Infect. Drug Resist.* **2023**, *2023*, 2561-2572, <https://doi.org/10.2147/IDR.S392087>.
  19. Bailey, C.J.; Day, C. Traditional Plant Medicines as Treatments for Diabetes. *Diabetes Care* **1989**, *12*, 553-564, <https://doi.org/10.2337/diacare.12.8.553>.
  20. Satpathy, L.; Parida, S.P. Therapeutic Role of *Curcuma longa* L. on Pulmonary Disorders: a Review. *Lett. Appl. NanoBioScience* **2024**, *13*, 5, <https://doi.org/10.33263/LIANBS131.005>.
  21. Mirza, H.; Kamrun, N.; Masayuki, F. Extreme Temperature Responses, Oxidative Stress and Antioxidant Defense in Plants. In *Abiotic Stress*, Kourosh, V., Charles, L., Eds.; IntechOpen, Rijeka, **2013**; Ch. 6, <http://dx.doi.org/10.5772/54833>.
  22. Ali, H.; Khan, E.; Ilahi, I. Environmental Chemistry and Ecotoxicology of Hazardous Heavy Metals: Environmental Persistence, Toxicity, and Bioaccumulation. *J. Chem.* **2019**, *2019*, 6730305, <https://doi.org/10.1155/2019/6730305>.
  23. Anjum, N.A.; Gill, S.S.; Duarte, A.C.; Pereira, E. Oxidative Stress Biomarkers and Antioxidant Defense in Plants Exposed to Metallic Nanoparticles. In *Nanomaterials and Plant Potential*, Husen, A., Iqbal, M., Eds.; Springer International Publishing, Cham, **2019**; 427-439, [https://doi.org/10.1007/978-3-030-05569-1\\_17](https://doi.org/10.1007/978-3-030-05569-1_17).
  24. Hasanuzzaman, M.; Bhuyan, M.H.M.B.; Zulfiqar, F.; Raza, A.; Mohsin, S.M.; Mahmud, J.A.; Fujita, M.; Fotopoulos, V. Reactive Oxygen Species and Antioxidant Defense in Plants under Abiotic Stress: Revisiting the Crucial Role of a Universal Defense Regulator. *Antioxidants* **2020**, *9*, 681, <https://doi.org/10.3390/antiox9080681>.
  25. Sharma, P.; Jha, A.B.; Dubey, R.S.; Pessarakli, M. Reactive Oxygen Species, Oxidative Damage, and Antioxidative Defense Mechanism in Plants under Stressful Conditions. *J. Bot.* **2012**, *2012*, 217037, <https://doi.org/10.1155/2012/217037>.
  26. Ali, M.A.; Fahad, S.; Haider, I.; Ahmed, N.; Ahmad, S.; Hussain, S.; Arshad, M. Oxidative Stress and Antioxidant Defense in Plants Exposed to Metal/Metalloid Toxicity. In *Reactive Oxygen, Nitrogen and Sulfur Species in Plants*, Hasanuzzaman, M., Fotopoulos, V., Nahar, K. Fujita, M., Eds.; John Wiley & Sons, **2019**; 353-370, <https://doi.org/10.1002/9781119468677.ch15>.
  27. Satpathy, L.; Parida, S.P. Acute Toxicity Assessment and Behavioral Responses Induced by Kandhamal haladi in Adult Zebrafish (*Danio rerio*). *Biointerface Res. Appl. Chem.* **2020**, *11*, 7368-7381, <https://doi.org/10.33263/BRIAC111.73687381>.
  28. Datta, P.S.; Deb, D.L.; Tyagi, S.K. Assessment of groundwater contamination from fertilizers in the Delhi area based on <sup>18</sup>O, NO<sub>3</sub><sup>-</sup> and K<sup>+</sup> composition. *J. Contam. Hydrol.* **1997**, *27*, 249-262, [https://doi.org/10.1016/S0169-7722\(96\)00099-X](https://doi.org/10.1016/S0169-7722(96)00099-X).
  29. Satpathy, L.; Parida, S. Neuroprotective Role of Curcumin Against Benzo[a]pyrene-Induced Neurodegeneration in Zebrafish. *Biointerface Res. Appl. Chem.* **2021**, *12*, 7311-7320, <https://doi.org/10.33263/BRIAC126.73117320>.
  30. Ahmed, A.; Saeed, A.; Ejaz, S.A.; Aziz, M.; Hashmi, M.Z.; Channar, P.A.; Abbas, Q.; Raza, H.; Shafiq, Z.; El-Seedi, H.R. Novel adamantyl clubbed iminothiazolidinones as promising elastase inhibitors: design, synthesis, molecular docking, ADMET and DFT studies. *RSC Adv.* **2022**, *12*, 11974-11991, <https://doi.org/10.1039/D1RA09318E>.
  31. Chauhan, K.; Singh, P.; Kumar, V.; Shukla, P.K.; Siddiqi, M.I.; Chauhan, P.M.S. Investigation of Ugi-4CC derived 1*H*-tetrazol-5-yl-(aryl) methyl piperazinyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid: Synthesis, Biology and 3D-QSAR analysis. *Eur. J. Med. Chem.* **2014**, *78*, 442-454, <https://doi.org/10.1016/j.ejmech.2014.03.069>.
  32. Lakshmi, H.S.; Devasena, T. In silico analysis of cubebinol for evaluating its efficiency against menacing respiratory ailments. *Indian J. Chem. Technol.* **2023**, *30*, 448-460, <https://doi.org/10.56042/ijct.v30i4.71631>.



33. Rani, P.; Rajak, B.K.; Singh, D.V. Physicochemical parameters for design and development of lead herbicide molecules: Is 'Lipinski's rule of 5' appropriate for herbicide discovery?. *Pest Manag. Sci.* **2023**, *79*, 1931-1943, <https://doi.org/10.1002/ps.7367>.
34. Massardi, A.; Bahry, S.S.; Rahmawati, N.A.; Shabirah, C.A.; Pangastuti, A. Bioactive Compounds from *Penicillium* sp. Inhibit Antiapoptotic Bcl-2, Bcl-XL and Mcl-1: An in silico Study. *Mol. Cell Biol. Sci.* **2023**, *7*, 81-89, <https://doi.org/10.21705/mcbs.v7i2.330>.
35. Kesar, S.; Paliwal, S.; Mishra, P.; Madan, K.; Chauhan, M.; Chauhan, N.; Verma, K.; Sharma, S. Identification of Novel Rho-Kinase-II Inhibitors with Vasodilatory Activity. *ACS Med. Chem. Lett.* **2020**, *11*, 1694-1703, <https://doi.org/10.1021/acsmchemlett.0c00126>.
36. Tripathi, N.; Paliwal, S.; Sharma, S.; Verma, K.; Gururani, R.; Tiwari, A.; Verma, A.; Chauhan, M.; Singh, A.; Kumar, D.; Pant, A. Discovery of Novel Soluble Epoxide Hydrolase Inhibitors as Potent Vasodilators. *Sci. Rep.* **2018**, *8*, 14604, <https://doi.org/10.1038/s41598-018-32449-4>.
37. Vanommeslaeghe, K.; Hatcher, E.; Acharya, C.; Kundu, S.; Zhong, S.; Shim, J.; Darian, E.; Guvench, O.; Lopes, P.; Vorobyov, I.; Mackerell Jr, A.D. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. *J. Comput. Chem.* **2010**, *31*, 671–690, <https://doi.org/10.1002/jcc.21367>.
38. Guterres, H.; Park, S.-J.; Zhang, H.; Perone, T.; Kim, J.; Im, W. CHARMM-GUI *high-throughput simulator* for efficient evaluation of protein–ligand interactions with different force fields. *Protein Sci.* **2022**, *31*, e4413, <https://doi.org/10.1002/pro.4413>.
39. Zhang, Y.; Simpson Alan, A.; Ledford Rebecca, M.; Bator Carol, M.; Chakravarty, S.; Skochko Gregory, A.; Demenczuk Tina, M.; Watanyar, A.; Pevear Daniel, C.; Rossmann Michael, G. Structural and Virological Studies of the Stages of Virus Replication That Are Affected by Antirhinovirus Compounds. *J. Virol.* **2004**, *78*, 11061-11069, <https://doi.org/10.1128/jvi.78.20.11061-11069.2004>.